CN1318026C - 含有莫达芬尼的固体药物制剂 - Google Patents

含有莫达芬尼的固体药物制剂 Download PDF

Info

Publication number
CN1318026C
CN1318026C CNB028104919A CN02810491A CN1318026C CN 1318026 C CN1318026 C CN 1318026C CN B028104919 A CNB028104919 A CN B028104919A CN 02810491 A CN02810491 A CN 02810491A CN 1318026 C CN1318026 C CN 1318026C
Authority
CN
China
Prior art keywords
modafinil
compositions
starch
weight
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028104919A
Other languages
English (en)
Chinese (zh)
Other versions
CN1511031A (zh
Inventor
文森特·科尔瓦里
乔治·格兰多尔菲
阿尔帕·帕里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26852708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1318026(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CN1511031A publication Critical patent/CN1511031A/zh
Application granted granted Critical
Publication of CN1318026C publication Critical patent/CN1318026C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB028104919A 2001-05-25 2002-05-24 含有莫达芬尼的固体药物制剂 Expired - Lifetime CN1318026C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29369501P 2001-05-25 2001-05-25
US60/293,695 2001-05-25
US10/155,913 2002-05-23
US10/155,913 US7297346B2 (en) 2001-05-25 2002-05-23 Pharmaceutical formulations of modafinil
PCT/US2002/016369 WO2002096401A1 (en) 2001-05-25 2002-05-24 Solid pharmaceutical formulations comprising modafinil

Publications (2)

Publication Number Publication Date
CN1511031A CN1511031A (zh) 2004-07-07
CN1318026C true CN1318026C (zh) 2007-05-30

Family

ID=26852708

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028104919A Expired - Lifetime CN1318026C (zh) 2001-05-25 2002-05-24 含有莫达芬尼的固体药物制剂

Country Status (19)

Country Link
US (1) US7297346B2 (enExample)
EP (1) EP1397127B8 (enExample)
JP (1) JP4443119B2 (enExample)
KR (1) KR100911779B1 (enExample)
CN (1) CN1318026C (enExample)
AT (1) ATE357228T1 (enExample)
AU (1) AU2002318155B8 (enExample)
BR (1) BRPI0210085B8 (enExample)
CA (1) CA2448456C (enExample)
DE (1) DE60219005T2 (enExample)
ES (1) ES2281527T3 (enExample)
IL (1) IL158959A (enExample)
MX (1) MXPA03010705A (enExample)
MY (1) MY129376A (enExample)
NO (1) NO328805B1 (enExample)
NZ (1) NZ530040A (enExample)
TW (1) TWI321475B (enExample)
WO (1) WO2002096401A1 (enExample)
ZA (1) ZA200309978B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101098749B1 (ko) 2000-07-27 2011-12-23 테바 파마슈티컬 인더스트리즈 리미티드 결정질의 순수한 모다피닐 및 이의 제조 방법
KR20040100835A (ko) 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
EP1526842A1 (en) * 2002-07-25 2005-05-04 Ranbaxy Laboratories, Ltd. Processes for the preparation of oral dosage formulations of modafinil
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
ES2487415T3 (es) * 2003-03-17 2014-08-20 Neurohealing Pharmaceuticals, Inc. Tratamiento dopaminérgico de alta potencia de deficiencias neurológicas asociadas con lesiones cerebrales
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
UA94380C2 (ru) * 2003-09-18 2011-05-10 Сефалон, Інк. Фармацевтические композиции модафинила с модифицированным высвобождением
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
JP2008535860A (ja) * 2005-04-08 2008-09-04 ニュー リヴァー ファーマシューティカルズ インク． 乱用抵抗性アンフェタミンプロドラッグ
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
KR101431711B1 (ko) * 2008-05-07 2014-08-21 삼성전자 주식회사 발광 장치 및 발광 시스템의 제조 방법, 상기 방법을이용하여 제조한 발광 장치 및 발광 시스템
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
WO2012078800A2 (en) 2010-12-08 2012-06-14 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
US20130267612A1 (en) * 2010-12-21 2013-10-10 Akzo Nobel Chemicals International B.V. Instant powders for aqueous cosmetic applications
FR2987266B1 (fr) 2012-02-28 2014-12-19 Debregeas Et Associes Pharma Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702968A1 (fr) * 1993-03-23 1994-09-30 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1570994A (en) 1923-11-20 1926-01-26 William A Cook Spring-forming die
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
GB9225492D0 (en) * 1992-12-05 1993-01-27 Glaxo Group Ltd Amine derivatives
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2706767B1 (enExample) 1993-06-22 1995-09-08 Lafon Labor
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
PT1140034E (pt) 1998-12-18 2004-03-31 Abbott Lab Formulacao de libertacao controlada de divalproex de sodio
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20010034373A1 (en) 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702968A1 (fr) * 1993-03-23 1994-09-30 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .

Also Published As

Publication number Publication date
BRPI0210085A (pt) 2004-06-29
TWI321475B (en) 2010-03-11
ZA200309978B (en) 2005-05-25
US7297346B2 (en) 2007-11-20
BRPI0210085B8 (pt) 2021-07-20
EP1397127B1 (en) 2007-03-21
AU2002318155B2 (en) 2007-03-01
BRPI0210085B1 (pt) 2020-11-10
NO328805B1 (no) 2010-05-18
US20030022940A1 (en) 2003-01-30
NZ530040A (en) 2005-11-25
JP4443119B2 (ja) 2010-03-31
WO2002096401A1 (en) 2002-12-05
MY129376A (en) 2007-03-30
HK1061652A1 (en) 2004-09-30
EP1397127A1 (en) 2004-03-17
KR20040005986A (ko) 2004-01-16
JP2004532863A (ja) 2004-10-28
IL158959A0 (en) 2004-05-12
MXPA03010705A (es) 2004-05-27
KR100911779B1 (ko) 2009-08-12
ES2281527T3 (es) 2007-10-01
IL158959A (en) 2010-06-30
AU2002318155B8 (en) 2008-05-15
CA2448456C (en) 2010-07-27
DE60219005D1 (de) 2007-05-03
NO20035211D0 (no) 2003-11-24
ATE357228T1 (de) 2007-04-15
EP1397127B8 (en) 2008-02-20
CA2448456A1 (en) 2002-12-05
CN1511031A (zh) 2004-07-07
DE60219005T2 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
CN1318026C (zh) 含有莫达芬尼的固体药物制剂
JP2014028833A (ja) モダフィニルの新規の医薬製剤
JP5702305B2 (ja) 有核型の口腔内崩壊錠
WO2005037254A1 (ja) 口腔内速崩壊性錠剤
AU2002318155A1 (en) Solid pharmaceutical formulations comprising modafinil
JP2001278812A (ja) 錠剤用崩壊剤及びこれを用いた錠剤
JP2002541107A (ja) トルペリソンを含有する経口投与のための薬学的製剤
JP4438121B2 (ja) 口腔内速崩錠及びその製造方法
JP2013533881A (ja) バノキセリンを含有する医薬組成物
US20100129444A1 (en) Novel Pharmaceutical Formulations of Modafinil
CN115708820B (zh) L-茶氨酸缓释制剂、双释放制剂、应用和药物
WO2005092319A1 (en) Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
HK1078265B (en) Novel pharmaceutical formulations of modafinil

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070530